Boehringer Ingelheim program for treatment of schizophrenia

Saniona entered into a drug discovery and development collaboration with Boehringer Ingelheim in 2016. The collaboration focuses on research of new small molecule therapeutics that could be capable of restoring brain network activity in patients with schizophrenia. By combining Saniona’s expertise in ion channels and related technology platforms with Boehringer Ingelheim’s expertise in research and clinical development as well as marketing of medicines, we are well positioned to advance new treatment options for schizophrenia.

In July 2018, Boehringer Ingelheim selected the first candidate for pre-clinical and clinical development under Saniona’s and Boehringer Ingelheim’s collaboration in schizophrenia.

The program is in the pre-clinical development phase.